文献速递肝病

综述:肠道微生物组在非酒精性脂肪性肝病进展中的新兴作用及治疗意义

Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications.
PubMed 文献 · Aliment Pharmacol Ther · 2019-05-31

本文为综述,通过PubMed检索文献,探讨肠道微生物组在NAFLD病理生理中的作用,包括肥胖、代谢综合征、疾病严重程度及纤维化进展的关联,并评估微生物组靶向治疗改善NAFLD治疗结局的潜力。结论认为多条病理生理通路连接肠道微生物组与NAFLD,有效靶向肠道微生物组的治疗可能对NAFLD患者有益。

要点

  • 肠道细菌组成可增强脂肪沉积、调节能量代谢并改变炎症过程。
  • 新证据提示肠道微生物组在肥胖和代谢综合征中起作用。
  • 有效靶向肠道微生物组的治疗可能对NAFLD患者有益。

核心结论

  • 多条病理生理通路连接肠道微生物组与NAFLD的病理生理。
  • 有效靶向肠道微生物组的治疗可能对NAFLD患者有益。

研究设计与样本

  • 综述,通过PubMed检索文献并纳入相关文章。

主要发现

  • 胃肠道细菌组成可增强脂肪沉积、调节能量代谢并改变炎症过程。
  • 新证据提示肠道微生物组在肥胖和代谢综合征中起作用。
  • 肠道微生物组组成与NAFLD疾病严重程度的关联已有大量进展。
  • 综述讨论了微生物组组成能否区分NAFL(非进展型)与NASH(进展型)。
  • 综述还讨论了肠道微生物组与NAFLD纤维化进展的关联。

临床怎么用

  • 综述评估了微生物组靶向治疗改善NAFLD患者治疗结局的潜力。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is a prevalent disorder associated with obesity and diabetes. Few treatment options are effective for patients with NAFLD, but connections between the gut microbiome and NAFLD and NAFLD-associated conditions suggest that modulation of the gut microbiota could be a novel therapeutic option. AIM: To examine the effect of the gut microbiota on pathophysiologic causes of NAFLD and assess the potential of microbiota-targeting therapies for NAFLD. METHODS: A PubMed search of the literature was performed; relevant articles were included. RESULTS: The composition of bacteria in the gastrointestinal tract can enhance fat deposition, modulate energy metabolism and alter inflammatory processes. Emerging evidence suggests a role for the gut microbiome in obesity and metabolic syndrome. NAFLD is often considered the hepatic manifestation of metabolic syndrome, and there has been tremendous progress in understanding the association of gut microbiome composition with NAFLD disease severity. We discuss the role of the gut microbiome in NAFLD pathophysiology and whether the microbiome composition can differentiate the two categories of NAFLD: nonalcoholic fatty liver (NAFL, the non-progressive form) vs nonalcoholic steatohepatitis (NASH, the progressive form). The association between gut microbiome and fibrosis progression in NAFLD is also discussed. Finally, we review whether modulation of the gut microbiome plays a role in improving treatment outcomes for patients with NAFLD. CONCLUSIONS: Multiple pathophysiologic pathways connect the gut microbiome with the pathophysiology of NAFLD. Therefore, therapeutics that effectively target the gut microbiome may be beneficial for the treatment of patients with NAFLD.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Jayakumar S, Loomba R. Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications. Aliment Pharmacol Ther. 2019. PMID: 31149745. doi:10.1111/apt.15314

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。